BlinkLab

Blinklab Signs Partnership for Clinical Trial with European INTER-PSY, Supporting US and EU Regulatory Approval and Future Market Adoption

Partnership with INTER-PSY to run a prospective clinical trial on early-diagnosis of autism.

BlinkLab Limited (ASX:BB1) (“BlinkLab” or the “Company”), an innovative digital healthcare company developing smartphone-based AI powered sensory assessments to aid in the diagnosis of neurodevelopmental conditions including autism and ADHD, is pleased to announce a research and clinical partnership with the INTER-PSY (“Agreement”) in the Netherlands (https://interpsy.interpsygroep.nl/).


Highlights

  • Prospective clinical data in young children with autism will optimise BlinkLab’s experimental and AI algorithms.
  • Partnership will accelerate BlinkLab’s path to US and European regulatory approval for autism and clinical adoption.
  • Partnership will support adoption of BlinkLab as a diagnostic tool within the autism diagnostic community in Europe.
  • As part of the larger SCANNER consortium in Europe, this study will also specifically address a need for accelerated autism diagnosis in females.
  • Commencement of FDA 510(k) registration trial on track for later this year.

As part of the Agreement, INTER-PSY will run a prospective study on the ability of the BlinkLab app to aid in diagnosis of autism in children between 2-6 years of age that are referred to INTER-PSY. By analysing the behavioural and physiological responses collected via the app, BlinkLab will aim to identify autism characteristics, potentially offering patients a more rapid, accessible and objective assessment method.

Through this partnership, INTER-PSY will use BlinkLab’s technology to evaluate whether the technology can enhance their diagnostic accuracy and efficiency in the clinic. This partnership between BlinkLab and INTER-PSY demonstrates the potential of an AI mobile health platform to improve and accelerate mental health diagnostics.

INTER-PSY Study and Preparations for FDA 510(k) Regulatory Trial

The INTER-PSY study, which mirrors the design of the upcoming FDA regulatory trial, will be conducted as a single-site, prospective, double-blind, within-subject comparison study (pre- registered). Data gathered from this collaboration will be pivotal in refining the final experimental parameters and optimising machine learning algorithms for BlinkLab’s 510(k) FDA registrational study, specifically targeting diagnostic applications. INTER-PSY is a large autism expertise centre in the Netherlands, offering diagnostics, guidance, and treatment for young children, adolescents, adults, and the elderly with psychological and psychiatric complaints.

Els Blijd-Hogewys, INTER-PSY, commented:

“INTER-PSY is committed to supporting young children with autism in an efficient and effective manner. Our goal is to implement a ‘no waiting time policy’ between diagnosis and the start of therapy, working collaboratively with clients to help them take control of their lives and minimise the impact of autism on daily tasks. Integrating objective measurements can help in the diagnostic process, offering significant benefits to children, their families, and our providers. We believe that BlinkLab's innovative AI platform presents a promising solution for sensory assessments in autism, delivering a short, pleasant and child-friendly test experience. Research will be conducted at INTER-PSY's Expertise Team for Young Children (<6 years). In the future, the instrument could also be valuable for adults with autism.

Unfortunately, the waiting lists for autism assessment for adults in the Netherlands are often as long as 2 to 3 years. Such an instrument may help accelerate this process.”

Mr. Brian Leedman, Chairman BlinkLab, commented:

“Australia has comparable wait times for diagnosis of autism as experienced in Europe and the US. Our BlinkLab technology has the potential to significantly reduce wait times through early diagnosis resulting in treatment at a formative age where early intervention can lead to better outcomes for children and their caregivers.”

Dr. Henk-Jan Boele, CEO BlinkLab, commented:

“Our collaboration with INTER-PSY is one of the final steps in the prospective validation of BlinkLab’s platform before we commence our FDA registration trial later this year. I’m deeply appreciative of INTER-PSY’s partnership on this critical journey. As part of the large SCANNER consortium in Europe, this study with INTER-PSY will also specifically address autism diagnosis in females. Our BlinkLab team is in the final phase of fine-tuning our AI models and algorithms to ensure they meet the highest standards of accuracy, safety, and efficiency. We remain fully committed to executing our strategy and delivering long-term value to all our stakeholders.”

About the SCANNER Consortium

The SCANNER Consortium in Europe, of which BlinkLab is a member, was recently awarded with a 5.3M Euros grant from the Dutch Research Council. The mission of this consortium is to investigate sex differences in autism at a gene, brain and behaviour level. Autism is diagnosed four times more often in men than in women (Autism Spectrum Disorder, APA, 2013). However, little is known about the biological mechanisms behind this disparity, or to what extent this overrepresentation in males is due to bias in the medical research that is also present during the diagnostic process.

Historically, female participants have often been excluded from medical studies, resulting in data being collected primarily from men and generalised to women (Merone et al., 2022).

Similar biases are present in basic research, where men are overrepresented due to the lack of the estrus cycle, resulting in a large gap in our basic biological and clinical knowledge.

This translates into real-life disadvantages for women with neurodivergent conditions, as doctors often ignore the behaviours presented by women. This means that women are less likely to be referred for diagnostic tests and receive timely support, with long-lasting negative consequences for their quality of life. It is therefore crucial to involve women at all levels of research.

Dr. Aleksandra Badura, Lead Investigator SCANNER, commented:

“Within SCANNER we aim to understand how genetic, neurophysiological and behavioural sex differences contribute to autistic traits, and distinguish these biological factors from possible diagnostic bias. Our long-term goal is to improve the diagnostic process for autism and other neurodivergent disorders by taking sex differences into account at all levels of research and diagnosis.”

In addition to INTER-PSY, BlinkLab collaborates in the SCANNER Consortium with Vrije Universiteit Amsterdam; Karakter - Academic Center for Child and Adolescent Psychiatry; Radboud University; Medical Center, Radboud University; Universiteit Utrecht; HAS green academy; Erasmus MC; Netherlands Institute for Neuroscience; Nivel – Netherlands Institute for Health Services Research; University of Twente; Philips Medical Systems Nederland B.V. (Philips MR); Nederlandse Vereniging voor Autisme; Arivis, Noldus Information Technology; Sophia Foundation; WOMEN Inc.; Female Autism Network of the Netherlands; Netherlands Autism Register; Generation R; National association of general practice mental health professionals; Alliantie Gender & Gezondheid; National network autism in young children; National network of child and adolescent psychiatry; Special Olympics Netherlands.


Click here for the full ASX Release

This article includes content from Blinklab Limited, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.

BB1:AU
BlinkLab Limited

BlinkLab Limited Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

The Conversation (0)
BlinkLab Limited

BlinkLab Limited


Keep reading...Show less

Revolutionising Mental Health Care Through Mobile Solutions

Logos of OpenAI and Microsoft with "Tech 5" on an abstract tech-themed background.

Tech 5: OpenAI/Microsoft Talks Get Tense, SoftBank Floats Arizona Robotics Hub

This week, Microsoft (NASDAQ:MSFT) and OpenAI's once tight alliance showed signs of strain, while Meta Platforms (NASDAQ:META) continued to source artificial intelligence (AI) talent from rival companies.

Meanwhile, SoftBank's (TSE:9434) CEO is considering a new chip and robotics venture in Arizona, and Google (NASDAQ:GOOGL) is looking to bring AI solutions to American cities.

Read on to dive deeper into this week's top tech stories.

Keep reading...Show less
Canadian flag waving in front of a mountain landscape.

Canada Makes Tech Leadership Moves: Axl Launches, Carney Shares Priorities at G7 Summit

Canada’s tech sector saw momentum this week, with announcements spanning venture capital and quantum computing, as well as global policy leadership news out of the G7 summit.

Keep reading...Show less
Hand touching AI hologram with tech circuit pattern.

Tech 5: Meta Plans Multibillion AI Bet, Apple Reveals iOS 26 at WWDC 2025

This week saw a flurry of activity in the tech world, from Apple's (NASDAQ:AAPL) new product announcements to Amazon's (NASDAQ:AMZN) massive infrastructure investment in Pennsylvania.

Meanwhile, NVIDIA's (NASDAQ:NVDA) European expansion and its role as an artificial intelligence (AI) powerhouse were all but cemented after a series of announcements at the Paris VivaTech Conference, and Mark Zuckerberg's Meta Platforms (NASDAQ:META) made big moves in the AI startup space.

Read on to dive deeper into this week's top tech stories.

Keep reading...Show less
3D model of an intricate oil reservoir.

Why 3D Visualisation is a Game Changer for Resource Asset Management

Forget spreadsheets and static blueprints. The future of resource asset management is unfolding in three dimensions, and smart money is starting to take notice.

3D visualisation is no longer a niche tool; it's rapidly becoming the indispensable core of how resource companies — such as mining, oil and gas and utilities — are tackling their most pressing challenges, from optimising daily operations to achieving critical environmental, social and governance objectives. For investors, this isn't just a technological upgrade; it's a paradigm shift with significant implications for portfolio performance.

Keep reading...Show less
Digital security concept with shield icon and abstract network design.

Tech 5: CoreWeave and Applied Digital Strike Deal, Startup Anduril Raises US$2.5 Billion

This week’s developments across the tech sector underscored the deepening connection between advanced computing, capital flows and geopolitical dynamics.

Applied Digital (NASDAQ:APLD) secured a landmark agreement with CoreWeave (NASDAQ:CRWV), while Broadcom’s (NASDAQ:AVGO) newest high-performance chip hit the market. Meanwhile, Canada’s Cohere is reportedly seeking fresh funding as it builds momentum in the enterprise artificial intelligence (AI) space.

In the defense sector, Anduril Industries secured a new round of funding, and elsewhere geopolitical tensions made their mark on Apple’s (NASDAQ:APPL) AI rollout in China.

Keep reading...Show less
Vancouver Convention Center and skyline.

Web Summit 2025: AI Innovation, Investment Shifts and Global Tech Alliances Take Center Stage

The Vancouver edition of Web Summit took place last week, bringing 15,727 attendees from 117 countries together, including 159 partners, 681 investors and 50 trade delegations.

A record-breaking 1,108 startups across a range of tech-touching industries exhibited, showcasing their products, services and ideas, from groundbreaking biotech advancements to revolutionary sustainable energy solutions.

Artificial intelligence (AI) was a prominent feature across all these innovations, underscoring the rapid pace of technological advancement and its pervasive influence across all aspects of modern life.

Keep reading...Show less
BlinkLab Limited

BlinkLab Limited Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

Latest Press Releases

Related News

×